HONG KONG, Jan 9, 2025 – (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently, Candid Therapeutics, an American pharmaceutical company focusing on the field of autoimmunity, announced three R&D cooperation transactions on TCE bispecific antibodies with a total potential transaction amount of over $1.32 billion…
Read More
